MedTrace Logo

Absorption and Metabolic Profiles of a Sugar-based Beverage

NCT02226250 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-01-26

No results posted yet for this study

Summary

Primary objective is to determine absorption profile of a sugar-based beverage on inflammatory mechanism by timing of beverage consumption relative to meal intake.

Secondary objective is to determine absorption profile of a sugar-based beverage on oxidative and metabolic mechanism by timing of beverage consumption relative to meal intake.

The results will be served as an internal reference or negative control group to compare with polyphenol containing studies from other studies.

Each subject will receive 3 identical placebo drinks at each time points: fasting (0h), with standardized breakfast meal (2h), and 2 hours after the breakfast meal (4h). A planned size of 12 will be recruited into this part of the study.

This study is a single-arm design utilizing a multiple sampling, and repeated measures paradigm to evaluate timing influence of consumption of sugar-based beverage associated acute effect on inflammatory markers.

Conditions

Interventions

DIETARY_SUPPLEMENT

3 Placebo Beverages

Sugar beverage 2 hr before meal, with meal and 2 hr after meal

Sponsors & Collaborators

  • Clinical Nutrition Research Center, Illinois Institute of Technology

    lead INDUSTRY

Principal Investigators

  • Britt Burton-Freeman, Ph.D · Illinois Institute of Technology

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-26
Primary Completion
2015-01-13
Completion
2015-02-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02226250 on ClinicalTrials.gov